Patents by Inventor Yuji Kazuta
Yuji Kazuta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210255191Abstract: Disclosed is: a fluorescent dye comprising a compound, a tautomer of the compound, or a salt of the compound or the tautomer; a labeled composite substance comprising the fluorescent dye and a composite substance which are bonded to each other; a composition containing the fluorescent dye or the labeled composite substance; and a method for acquiring information about a substance of interest by a super-resolution microscopy.Type: ApplicationFiled: February 1, 2021Publication date: August 19, 2021Applicants: Eisai R&D Management Co., Ltd., SYSMEX CORPORATIONInventors: Daiki HARA, Takafumi Motoki, Yuji Kazuta, Yoshihiko Norimine, Hiroyuki Amino, Masatoshi Suganuma, Shingo Fujiyama, Kazuto Yamashita, Masaya Okada, Yoichi Nishikawa, Shigeki Iwanaga
-
Patent number: 9610262Abstract: The present invention is directed to a method of treating pain comprising the administering the following 1-indansulfamide compounds: N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (?)-N-(7-chloro-2,2,5-trifluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, N-[(1S)-2,2-difluoro-7-methyl-2,3-dihydro-1H-inden-1-yl]sulfamide, and N-[(1S)-2,2,5-trifluoro-7-methyl-2,3-dihydro-1H-inden-1-yl]sulfamide.Type: GrantFiled: December 17, 2014Date of Patent: April 4, 2017Assignee: Eisai R&D Management Co., Ltd.Inventors: Hiroyuki Higashiyama, Yuji Kazuta, Keisuke Hashimoto
-
Publication number: 20160303058Abstract: A medicine comprising a 1-indansulfamides compound such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, or N-[(1S)-2,2-difluoro-7-methyl-2,3-dihydro-1H-indene-1-yl]sulfamide or a pharmaceutically acceptable salt thereof, has an analgesic effects in the mouse hot-plate test and rat constriction nerve injury model and thus holds promise as a therapeutic agent for acute and chronic pain.Type: ApplicationFiled: December 17, 2014Publication date: October 20, 2016Inventors: Hiroyuki Higashiyama, Yuji Kazuta, Keisuke Hashimoto
-
Patent number: 9416109Abstract: The present disclosure provides compounds and methods that are useful for the preparation of compounds useful as orexin-2 receptor antagonists.Type: GrantFiled: February 14, 2013Date of Patent: August 16, 2016Assignee: Eisai R&D Management Co., Ltd.Inventors: George Anthony Moniz, Annie Zhu Wilcoxen, Farid Benayoud, Jaemoon Lee, Huiming Zhang, Taro Terauchi, Ayumi Takemura, Yu Yoshida, Toshiaki Tanaka, Keiichi Sorimachi, Yoshimitsu Naoe, Yuji Kazuta
-
Patent number: 9018260Abstract: Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.Type: GrantFiled: June 17, 2013Date of Patent: April 28, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuji Kazuta, Toru Watanabe, Keiichi Sorimachi, Minako Saito, Yoichi Kita, Toshiaki Tanaka, Hiroyuki Higashiyama, Takahisa Hanada, Tetsuyuki Teramoto, Takashi Kosasa, Yukio Ishikawa
-
Publication number: 20150025237Abstract: The present disclosure provides compounds and methods that are useful for the preparation of compounds useful as orexin-2 receptor antagonists.Type: ApplicationFiled: February 14, 2013Publication date: January 22, 2015Inventors: George Anthony Moniz, Annie Zhu Wilcoxen, Farid Benayoud, Jaemoon Lee, Huiming Zhang, Taro Terauchi, Ayumi Takemura, Yu Yoshida, Toshiaki Tanaka, Keiichi Sorimachi, Yoshimitsu Naoe, Yuji Kazuta
-
Publication number: 20140371319Abstract: Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.Type: ApplicationFiled: June 17, 2013Publication date: December 18, 2014Applicant: Eisai R&D Management Co., Ltd.Inventors: Yuji Kazuta, Toru Watanabe, Keiichi Sorimachi, Minako Saito, Yoichi Kita, Toshiaki Tanaka, Hiroyuki Higashiyama, Takahisa Hanada, Tetsuyuki Teramoto, Takashi Kosasa, Yukio Ishikawa
-
Patent number: 8268848Abstract: A cyclopropane compound represented by the following formula (A) or a pharmaceutically acceptable salt thereof has orexin receptor antagonism, and therefore has a potencial of usefulness for the treatment of sleep disorder for which orexin receptor antagonism is effective, for example, insomnia: wherein Q represents —CH— or a nitrogen atom, R1a and R1b each independently represent a C1-6 alkyl group and the like, R1c represents a hydrogen atom and the like, R2a, R2b, R2c and R2d each independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group and the like, R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom and the like, and R3d represents a hydrogen atom and the like.Type: GrantFiled: September 20, 2011Date of Patent: September 18, 2012Assignee: Eisai R&D Management Co., Ltd.Inventors: Taro Terauchi, Ayumi Takemura, Takashi Doko, Yu Yoshida, Toshiaki Tanaka, Keiichi Sorimachi, Yoshimitsu Naoe, Carsten Beuckmann, Yuji Kazuta
-
Publication number: 20120165339Abstract: A cyclopropane derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof has orexin receptor inhibitory action, and thus, is extremely useful as an agent for preventing or treating sleep disorder or dyssomnia caused by orexin, including insomnia as a typical example: wherein A1, A2 and A3 each independently represent an aryl group, a heterocyclyl group or the like, R1, R2 and R3 each independently represent a hydrogen atom, a C1-6 alkyl group or the like, X represents an oxygen atom or the like, and L represents a bond or the like.Type: ApplicationFiled: December 20, 2011Publication date: June 28, 2012Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Taro Terauchi, Ayumi Takemura, Yuji Kazuta, Fumihiro Ozaki, Takashi Doko, Yu Yoshida, Toshiaki Tanaka, Keiichi Sorimachi, Yoshimitsu Naoe, Carsten Beuckmann
-
Publication number: 20120095031Abstract: A cyclopropane compound represented by the following formula (A) or a pharmaceutically acceptable salt thereof has orexin receptor antagonism, and therefore has a potencial of usefulness for the treatment of sleep disorder for which orexin receptor antagonism is effective, for example, insomnia: wherein Q represents —CH— or a nitrogen atom, R1a and R1b each independently represent a C1-6 alkyl group and the like, R1c represents a hydrogen atom and the like, R2a, R2b, R2c and R2d each independently represent a hydrogen atom, a halogen atom, a C1-6 alkyl group and the like, R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom and the like, and R3d represents a hydrogen atom and the like.Type: ApplicationFiled: September 20, 2011Publication date: April 19, 2012Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Taro Terauchi, Ayumi Takemura, Takashi Doko, Yu Yoshida, Toshiaki Tanaka, Keiichi Sorimachi, Yoshimitsu Naoe, Carsten Beuckmann, Yuji Kazuta
-
Publication number: 20090318690Abstract: Disclosed is a compound represented by the general formula (I) or a salt thereof: wherein any one of R1, R2 and R3 represents a group represented by the formula: —(CH2)m-NR11R12 (wherein m is 1 or 2; and R11 and R12 independently represent a hydrogen atom or a C1-6 alkyl group or may, together with a nitrogen atom to which R11 and R12 are bound, form a 4- or 5-membered cyclic group); the remaining two or R1, R2 and R3 independently represent a group represented by the formula: —(O)n-R21 (wherein n is 0 or 1; and R21 represents a hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or the like); and R4 represents a C1-6 alkyl group which may have a substituent or the like.Type: ApplicationFiled: April 27, 2007Publication date: December 24, 2009Applicant: Eisai R&D Management Co., Ltd.Inventors: Atsushi Sasaki, Kohshi Ueno, Yuichi Suzuki, Shinichi Hamaoka, Daisuke Shimmyo, Yoshinori Takahashi, Toshiki Kurokawa, Yuji Kazuta, Hiroo Ogura, Tatsuto Fukushima